Legislation drafted by Sen. Kay Hagan (D-N.C.) in collaboration with BIO seeks to create an FDA progressive approval pathway that could expand accelerated approval to include virtually all new molecular entities.

The Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act also would give FDA authority to approve compounds based on approvals in Europe and some other countries.